McKesson Ventures Invests as Clinical Ink Debuts Lunexis™ ePRO+ Solution
Summary
Clinical Ink’s innovative eSource solutions are particularly well-positioned as the industry shifts to more decentralized trials and remote monitoring,” said Dave Schulte, senior vice president and managing director of McKesson Ventures. Despite the higher complexity this flexibility might suggest, ePRO+ still supports the rapid system implementation Clinical Ink is known for, with study builds now less than 30 days, including translations. “As the eSource pioneers with tens of thousands of site-user interactions behind us, we know our solutions must be adaptable to patients’ and sites’ day-to-day realities,” said Clinical Ink CEO Ed Seguine. Mixed-modality capabilities, associated changes to the clinician-reported outcomes (ClinRO) feature set, and time-saving, unified authoring allow for extreme flexibility and are ideal for a wide variety of physical, virtual, and hybrid clinical trials. By harnessing this vision and years of experience, this launch builds even more momentum and positions Clinical Ink to continue in its role as industry leader well into the future.
Classifications
AskAI Classifications
LabelsLinked Companies
